|
melanoma
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|
|
melanoma
|
0.500 |
CausalMutation
|
disease |
CGI |
|
|
|
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Thus in human melanoma PH domain mutations of PKB/Akt do not play a major role in melanoma carcinogenesis.
|
11828257 |
2002 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
LHGDN |
Thus in human melanoma PH domain mutations of PKB/Akt do not play a major role in melanoma carcinogenesis.
|
11828257 |
2002 |
|
melanoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression.
|
12499277 |
2002 |
|
melanoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
These data link AKT activation with MelCAM expression, and implicate that intervention of MelCAM-AKT signaling axis in melanoma is a potential therapeutical approach.
|
14534536 |
2003 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In this study, we elucidated the involvement of the up-regulation of RAS/MAPK and PI3K/AKT cascades in the pathogenesis of endometrial cancer and melanoma by analyzing the genes and molecules in these cascades.
|
16273242 |
2005 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In summary, epigenetic PTEN silencing seems to be a relevant mechanism of inactivating this tumor suppressor gene in melanoma that may promote melanoma development by derepression of the AKT pathway.
|
16818626 |
2006 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our data uncover an unsuspected role of HH-GLI signaling in melanocytes and melanomas, demonstrate a role for this pathway in RAS-induced tumors, suggest a general integration of the RAS/AKT and HH-GLI pathways, and open a therapeutic approach for human melanomas.
|
17392427 |
2007 |
|
melanoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In this review, we discuss the RAS-RAF-MAP kinase and the RAS-PI3K-AKT pathway in detail, as up to 80% of cutaneous melanomas exhibit a BRAF mutation.
|
17492934 |
2007 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Herein, we examined whether targeting the RAS-RAF-MEK-ERK pathway with the RAF inhibitor sorafenib and/or the PI3K-AKT-mTOR pathway with the mTOR inhibitor rapamycin has therapeutic effects against melanoma.
|
18323781 |
2008 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
LHGDN |
The release of fibroblast growth factor-1 from melanoma cells requires copper ions and is mediated by phosphatidylinositol 3-kinase/Akt intracellular signaling pathway.
|
18400376 |
2008 |
|
melanoma
|
0.500 |
AlteredExpression
|
disease |
LHGDN |
Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma.
|
18509361 |
2008 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This represents the first report of AKT mutations in melanoma, and the initial identification of an AKT3 mutation in any human cancer lineage.
|
18813315 |
2008 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
LHGDN |
Milk fat globule EGF-8 promotes melanoma progression through coordinated Akt and twist signaling in the tumor microenvironment.
|
18974133 |
2008 |
|
melanoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In parallel, we assessed several human melanoma biopsy samples and found again that AKT2 was the predominantly activated AKT in these human melanoma biopsies.
|
19843246 |
2010 |
|
melanoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Expression of phospho-AKT Thr308 was associated with metastatic uvea melanomas.
|
20173664 |
2010 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Results show that KIT mutations are more common in vulvar melanomas than other types of mucosal melanomas and that both the RAF/MEK/ERK and PI3K/AKT pathways are activated in mucosal melanoma specimens.
|
21680547 |
2011 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
MAPK and PI3K/AKT mediated YB-1 activation promotes melanoma cell proliferation which is counteracted by an autoregulatory loop.
|
22417301 |
2012 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Finally, use of inhibitors to target downstream signaling through mitogen-activated protein kinase kinase and phosphatidylinositol 3-OH kinase or AKT are now entering clinical trials, and if these combinations can be safely delivered at sufficient dose to inhibit the targets, there is significant potential to target NRAS mutant melanoma.
|
22453013 |
2012 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In addition, functional experiments have demonstrated important roles for the PI3K-AKT pathway in both melanoma initiation and therapeutic resistance.
|
22453015 |
2012 |
|
melanoma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
Moreover, SBF-1 inhibited the growth of melanoma xenografts and down-regulated the phosphorylation of AKT in vivo.
|
22525724 |
2012 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Recent evidence supports miRNA dysregulation in melanoma impacting several well-known pathways such as the PI3K/AKT or RAS/MAPK pathways, but also underexplored cellular processes like protein glycosylation and immune modulation.
|
22693259 |
2012 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion.
|
22911700 |
2012 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Simultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit melanoma.
|
23112250 |
2013 |